In line with this, a recent study has identified the increased expression of E2F1 in human NAFLD, and that increased E2F1 can function as a metabolic driver of NAFLD-related hepatocellular carcinoma [26]. This evidence concerns the gene E2F1 and metabolic dysfunction-associated steatotic liver disease.